DOCSLIB.ORG

211172Orig1s000

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
211172Orig1s000 CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 211172Orig1s000 CLINICAL REVIEW(S) Combined Clinical/Biostatistical Review Clinical Reviewer – Breder; Statistical Reviewer – Massie NDA 211172 Tegsedi (inotersen) CLINICAL REVIEW Application Type Original NDA Application Number(s) 211172 Priority or Standard Priority Submit Date(s) 11/6/17 Received Date(s) 11/6/17 PDUFA Goal Date 10/6/18 (Extension); 7/6/18 (Original) Division/Office DNP/ODEI Reviewer Name(s) Clinical Reviewer – Christopher Breder; Statistical Reviewer – Tristan Massie Review Completion Date October 4, 2018 Established/Proper Name Inotersen (Proposed) Trade Name Tegsedi Applicant Ionis Pharmaceuticals, Inc. Dosage Form(s) 284 mg inotersen (300 mg sodium salt)/ 1.5 mL in a single- dose, prefilled syringe including a safety syringe device. Applicant Proposed (b) (4) Dosing Regimen(s) doses should be administered once every week (b) (4) Applicant Proposed For treatment of adult patients with hereditary TTR amyloidosis Indication(s)/Population(s) with polyneuropathy (hATTR-PN) (b) (4) Recommendation on Substantial evidence of effectiveness has been provided Regulatory Action Recommended For treatment of the polyneuropathy of hereditary transthyretin- Indication(s)/Population(s) mediated amyloidosis (if applicable) 1 Reference ID: 4330479 Combined Clinical/Biostatistical Review Clinical Reviewer – Breder; Statistical Reviewer – Massie NDA 211172 Tegsedi (inotersen) Table of Contents Glossary .......................................................................................................................................... 6 1. Executive Summary ................................................................................................................. 8 1.1. Product Introduction ......................................................................................................... 8 1.2. Conclusions on the Substantial Evidence of Effectiveness .............................................. 8 1.3. Benefit-Risk Assessment.................................................................................................. 9 1.4. Patient Experience Data ................................................................................................. 12 2. Therapeutic Context .............................................................................................................. 13 2.1. Analysis of Condition..................................................................................................... 13 2.2. Analysis of Current Treatment Options ......................................................................... 14 3. Regulatory Background ......................................................................................................... 14 3.1. U.S. Regulatory Actions and Marketing History ........................................................... 14 3.2. Summary of Presubmission/Submission Regulatory Activity ....................................... 15 3.3. Foreign Regulatory Actions and Marketing History ...................................................... 15 4. Significant Issues from Other Review Disciplines Pertinent to Clinical Conclusions on Efficacy and Safety ............................................................................................................... 15 4.1. Office of Scientific Investigations (OSI) ....................................................................... 15 4.2. Product Quality ............................................................................................................. 16 4.3. Clinical Microbiology .................................................................................................... 16 4.4. Nonclinical Pharmacology/Toxicology.......................................................................... 16 4.5. Clinical Pharmacology ................................................................................................... 17 5. Sources of Clinical Data and Review Strategy ...................................................................... 17 5.1. Table of Clinical Studies ................................................................................................ 17 5.2. Review Strategy ............................................................................................................. 18 6. Review of Relevant Individual Trials Used to Support Efficacy .......................................... 18 6.1. Study 1 (“ISIS 420915-CS2”, “CS2”): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ISIS 420915 in Patients with Familial Amyloid Polyneuropathy (NEURO-TTR Study) ....................................................... 18 6.1.1. Study Design ........................................................................................................... 18 6.1.2. Overview and Objective ......................................................................................... 18 6.1.3. Trial Design ............................................................................................................ 18 2 Reference ID: 4330479 Combined Clinical/Biostatistical Review Clinical Reviewer – Breder; Statistical Reviewer – Massie NDA 211172 Tegsedi (inotersen) 6.1.4. Regimen .................................................................................................................. 18 6.1.5. Study Results .......................................................................................................... 36 6.2. ISIS 420915-CS3: An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of ISIS 420915 in Patients with Familial Amyloid Polyneuropathy (FAP) ........ 64 6.2.1. Study Design ........................................................................................................... 64 6.2.2. Study Results .......................................................................................................... 67 6.3. Abbreviated Description of Clinical Study Report 420915-CS1: A Double Blind, Placebo-Controlled, Dose-Escalation, Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of ISIS 420915 Administered Subcutaneously to Healthy Volunteers (ISIS Study Number ............................................................................. 76 6.3.1. Study Design ........................................................................................................... 76 6.3.2. Study Results .......................................................................................................... 77 Disposition ........................................................................................................................ 77 7. Review of Safety ................................................................................................................... 78 8. Advisory Committee Meeting and Other External Consultations ......................................... 78 9. Labeling Recommendations .................................................................................................. 78 9.1. Prescription Drug Labeling ............................................................................................ 79 10. Risk Evaluation and Mitigation Strategies (REMS) .............................................................. 79 11. Postmarketing Requirements and Commitments .................................................................. 79 12. Appendices ............................................................................................................................ 80 12.1. Financial Disclosure ................................................................................................... 80 13. References ............................................................................................................................. 81 3 Reference ID: 4330479 Combined Clinical/Biostatistical Review Clinical Reviewer – Breder; Statistical Reviewer – Massie NDA 211172 Tegsedi (inotersen) Table of Tables Table 1 Listing of Clinical Trials Relevant to this NDA ............................................................. 17 Table 2 Stages of Amyloid Polyneuropathy[3] ............................................................................ 20 Table 3 Scoring for the NIS composite score ............................................................................... 25 Table 4 Scoring for the m+7 Composite Score ............................................................................. 26 Table 5 Amendments by Country Version of the CS2 Protocol ................................................... 34 Table 6 Disposition of Patients ..................................................................................................... 38 Table 7 Number of Patients by Analysis Dataset (% of Total)..................................................... 39 Table 8 Demographic Characteristics ........................................................................................... 40 Table 9 Other Baseline Characteristics (e.g., disease characteristics, concomitant drugs) .......... 41 Table 10 Imbalances in Baseline Demographics Identified by Applicant .................................... 43 Table 11 Exposure to Drug in Study CS2 ..................................................................................... 45 Table 12 Evaluation of mNIS+7 by Subgroup ............................................................................. 48 Table 13 Norfolk QoL-DN by Stratification
Load more

Recommended publications
  • Specialty Pipeline Monthly Update
    Specialty Pipeline Monthly Update Critical updates in an ever changing environment May 2019 New drug information ● Skyrizi™ (risankizumab-rzaa): AbbVie’s Skyrizi, a biologic that selectively blocks interleukin-23 (IL-23) received U.S. Food and Drug Administration (FDA) approval for the treatment of moderate-to- severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. It will directly compete with Janssen’s Tremfya® and Sun’s Illumya® in this market space as well as with other biologic drugs commonly used for plaque psoriasis (i.e., AbbVie’s Humira®, Novartis’ Cosentyx®, and J&J’s Stelara®). Skyrizi has an annual wholesale acquisition cost (WAC) of $88,500 for the first year which includes loading doses, and $59,000 yearly thereafter. AbbVie notes this is cheaper than most widely prescribed biologic treatment for moderate to severe plaque psoriasis.1 ● Eticovo™ (etanercept-ykro): The second biosimilar referencing Amgen/Pfizer’s Enbrel® (etanercept) was approved by the FDA for Samsung Bioepis’ Eticovo for the treatment of certain patients with rheumatoid arthritis, polyarticular juvenile idiopathic arthritis; psoriatic arthritis; ankylosing spondylitis and plaque psoriasis. Sandoz’s Erelzi is also a biosimilar referencing Enbrel. Neither Samsung Bioepis or Sandoz have released their launch plans; however, depending on patent litigation Enbrel could lose exclusivity either in 2019 or 2029. ● Vyndaqel® (tafamidis meglumine) and Vyndamax™ (tafamidis): Pfizer received FDA approval for both Vyndaqel and Vyndamax, for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular- related hospitalization. The FDA approved dose is either Vyndamax 61 mg (1 capsule) once daily, or Vyndaqel 80 mg (four-20 mg capsules) once daily, both achieve the same effectiveness in cardiomyopathy.
    [Show full text]
  • Horizon Scanning Status Report June 2019
    Statement of Funding and Purpose This report incorporates data collected during implementation of the Patient-Centered Outcomes Research Institute (PCORI) Health Care Horizon Scanning System, operated by ECRI Institute under contract to PCORI, Washington, DC (Contract No. MSA-HORIZSCAN-ECRI-ENG- 2018.7.12). The findings and conclusions in this document are those of the authors, who are responsible for its content. No statement in this report should be construed as an official position of PCORI. An intervention that potentially meets inclusion criteria might not appear in this report simply because the horizon scanning system has not yet detected it or it does not yet meet inclusion criteria outlined in the PCORI Health Care Horizon Scanning System: Horizon Scanning Protocol and Operations Manual. Inclusion or absence of interventions in the horizon scanning reports will change over time as new information is collected; therefore, inclusion or absence should not be construed as either an endorsement or rejection of specific interventions. A representative from PCORI served as a contracting officer’s technical representative and provided input during the implementation of the horizon scanning system. PCORI does not directly participate in horizon scanning or assessing leads or topics and did not provide opinions regarding potential impact of interventions. Financial Disclosure Statement None of the individuals compiling this information have any affiliations or financial involvement that conflicts with the material presented in this report. Public Domain Notice This document is in the public domain and may be used and reprinted without special permission. Citation of the source is appreciated. All statements, findings, and conclusions in this publication are solely those of the authors and do not necessarily represent the views of the Patient-Centered Outcomes Research Institute (PCORI) or its Board of Governors.
    [Show full text]
  • May 2019 New Drugs
    May 2019 Learn more New drugs Drug name Therapeutic category Indication(s) Launch information Manufacturer(s) ® Dengvaxia For the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4. Dengvaxia is approved for use in (dengue tetravalent vaccine, Vaccine individuals 9 through 16 years of age with laboratory- TBD live)* confirmed previous dengue infection and living in endemic Sanofi Pasteur areas. Ingrezza® (valbenazine) Vesicular monoamine initiation pack Treatment of adults with tardive dyskinesia April 22, 2019 transporter-2 inhibitor Neurocrine Biosciences ® Nayzilam (midazolam)† Acute treatment of intermittent, stereotypic episodes of frequent seizure activity (ie, seizure clusters, acute repetitive single-dose nasal spray Benzodiazepine TBD seizures) that are distinct from a patient’s usual seizure UCB pattern in patients with epilepsy 12 years of age and older In combination with Faslodex® (fulvestrant) for the treatment ® of postmenopausal women, and men, with hormone receptor- Piqray (alpelisib)* Phosphoinositide 3-kinase CA positive, human epidermal growth factor receptor 2-negative, May 30, 2019 Novartis inhibitor PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen 1 RxHighlights May 2019 Drug name Therapeutic category Indication(s) Launch information Manufacturer(s) ® Qternmet XR Sodium-glucose cotransporter 2 (dapagliflozin/saxagliptin/ Adjunct to diet and exercise to improve glycemic control in inhibitor/dipeptidyl
    [Show full text]
  • Foldrx Pharmaceuticals, a Pfizer Company a Multicenter, International, Phase 3, Double-Blind, Placebo-Controlled, Randomized
    PF-06291826 Tafamidis Meglumine B3461028 Final Protocol Amendment 3, 24 May 2016 FOLDRX PHARMACEUTICALS, A PFIZER COMPANY A MULTICENTER, INTERNATIONAL, PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE (PF-06291826) 20 MG OR 80 MG IN COMPARISON TO PLACEBO IN SUBJECTS DIAGNOSED WITH TRANSTHYRETIN CARDIOMYOPATHY (TTR-CM) Compound: PF-06291826 Compound Name: tafamidis US IND Number: IND 71,880 European Clinical Trial Database 2012-002465-35 (EudraCT) Number: Protocol Number: B3461028 Phase: 3 Page 1 PF-06291826 Tafamidis Meglumine B3461028 Final Protocol Amendment 3, 24 May 2016 Document History Document Version Date Summary of Changes Original protocol 31 Jul 2013 N/A Amendment 1 16 Apr 2014 Following initiation of the study the following changes were made to the study protocol: 1. Typographical corrections and clarifications. 2. Added the results of the B3461031 study indicating a lack of tafamidis effect on QTc. 3. Clarified the target sample size as 400 subjects. 4. Added “Smoking and Alcohol Classification” to the Schedule of Activities. 5. Removed Serum Amyloid A from required Screening analysis as it is an indicator of an active inflammatory process and does not contribute to defining an appropriate subject for this study. 6. Amended the Week 2 follow-up to allow for flexibility in scheduling a visit to either the investigator’s clinic or their primary care physician’s office or a visit to a local laboratory for blood collection (which would also include, a phone call). 7. The second 6MWT during Screening was removed in order to ease the burden of site visits.
    [Show full text]
  • CDER Breakthrough Therapy Designation Approvals Data As of December 31, 2020 Total of 190 Approvals
    CDER Breakthrough Therapy Designation Approvals Data as of December 31, 2020 Total of 190 Approvals Submission Application Type and Proprietary Approval Use Number Number Name Established Name Applicant Date Treatment of patients with previously BLA 125486 ORIGINAL-1 GAZYVA OBINUTUZUMAB GENENTECH INC 01-Nov-2013 untreated chronic lymphocytic leukemia in combination with chlorambucil Treatment of patients with mantle cell NDA 205552 ORIGINAL-1 IMBRUVICA IBRUTINIB PHARMACYCLICS LLC 13-Nov-2013 lymphoma (MCL) Treatment of chronic hepatitis C NDA 204671 ORIGINAL-1 SOVALDI SOFOSBUVIR GILEAD SCIENCES INC 06-Dec-2013 infection Treatment of cystic fibrosis patients age VERTEX PHARMACEUTICALS NDA 203188 SUPPLEMENT-4 KALYDECO IVACAFTOR 21-Feb-2014 6 years and older who have mutations INC in the CFTR gene Treatment of previously untreated NOVARTIS patients with chronic lymphocytic BLA 125326 SUPPLEMENT-60 ARZERRA OFATUMUMAB PHARMACEUTICALS 17-Apr-2014 leukemia (CLL) for whom fludarabine- CORPORATION based therapy is considered inappropriate Treatment of patients with anaplastic NOVARTIS lymphoma kinase (ALK)-positive NDA 205755 ORIGINAL-1 ZYKADIA CERITINIB 29-Apr-2014 PHARMACEUTICALS CORP metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib Treatment of relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, in patients NDA 206545 ORIGINAL-1 ZYDELIG IDELALISIB GILEAD SCIENCES INC 23-Jul-2014 for whom rituximab alone would be considered appropriate therapy due to other co-morbidities
    [Show full text]
  • Long-Term Safety and Efficacy of Tafamidis for the Treatment of Hereditary Transthyretin Amyloid Polyneuropathy: Results up to 6 Years
    AMYLOID, 2017 VOL. 24, NO. 3, 194–204 https://doi.org/10.1080/13506129.2017.1357545 ORIGINAL ARTICLE Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years Fabio A. Barrosoa, Daniel P. Judgeb, Ben Ebedec, Huihua Lic, Michelle Stewartc, Leslie Amassc and Marla B. Sultanc aDepartment of Neurology, Institute for Neurological Research Raul Carrea, FLENI, Buenos Aires, Argentina; bJohns Hopkins University Center for Inherited Heart Disease, Baltimore, MD, USA; cPfizer Inc, New York, NY, USA ABSTRACT ARTICLE HISTORY Background: The objective of the present study was to evaluate the long-term safety and efficacy of Received 22 November 2016 tafamidis in treating hereditary transthyretin amyloid polyneuropathy. Revised 13 July 2017 Methods: A prospectively planned interim analysis was conducted on an on-going, phase III, open-label Accepted 17 July 2017 extension study following an 18-month, randomized, controlled study and 12-month, open-label exten- KEYWORDS sion study in ATTRV30M patients and a single-arm, open-label study in non-ATTRV30M patients. Thirty- Amyloidosis; disease- seven ATTRV30M patients received placebo for 18 months, then switched to tafamidis and 38 ATTRV30M modifying drug; non- patients and 18 non-ATTRV30M patients continuously received tafamidis from day 1, up to 6 years. ATTRV30M; ATTRV30M Results: Long-term tafamidis was associated with a favourable safety/tolerability profile, without any unexpected adverse events. Patients initiating tafamidis at the start of the randomized study had less polyneuropathy progression versus those switching to tafamidis following 18 months of placebo and were less likely to progress to the next ambulatory stage after up to 6 years follow-up.
    [Show full text]
  • Specialty Pharmacy Program Drug List
    Specialty Pharmacy Program Drug List The Specialty Pharmacy Program covers certain drugs commonly referred to as high-cost Specialty Drugs. To receive in- network benefits/coverage for these drugs, these drugs must be dispensed through a select group of contracted specialty pharmacies or your medical provider. Please call the BCBSLA Customer Service number on the back of your member ID card for information about our contracted specialty pharmacies. All specialty drugs listed below are limited to the retail day supply listed in your benefit plan (typically a 30-day supply). As benefits may vary by group and individual plans, the inclusion of a medication on this list does not imply prescription drug coverage. Please refer to your benefit plan for a complete list of benefits, including specific exclusions, limitations and member cost-sharing amounts you are responsible for such as a deductible, copayment and coinsurance. Brand Name Generic Name Drug Classification 8-MOP methoxsalen Psoralen ACTEMRA SC tocilizumab Monoclonal Antibody/Arthritis ACTHAR corticotropin Adrenocortical Insufficiency ACTIMMUNE interferon gamma 1b Interferon ADCIRCA tadalafil Pulmonary Vasodilator ADEMPAS riociguat Pulmonary Vasodilator AFINITOR everolimus Oncology ALECENSA alectinib Oncology ALKERAN (oral) melphalan Oncology ALUNBRIG brigatinib Oncology AMPYRA ER dalfampridine Multiple Sclerosis APTIVUS tipranavir HIV/AIDS APOKYN apomorphine Parkinson's Disease ARCALYST rilonacept Interleukin Blocker/CAPS ATRIPLA efavirenz-emtricitabine-tenofovir HIV/AIDS AUBAGIO
    [Show full text]
  • Tafamidis for Transthyretin Familial Polyneuropathy (TTR-FAP) Evidence Review Group Assessment of Manufacturer Submission
    Tafamidis for Transthyretin Familial Polyneuropathy (TTR-FAP) Evidence Review Group assessment of manufacturer submission Produced by CRD/CHE Technology Assessment Group (Centre for Reviews and Dissemination/Centre for Health Economics), University of York Authors Rita Faria, Research Fellow; Simon Walker, Research Fellow; Stephen Palmer, Professor Centre for Health Economics Mark Corbett, Research Fellow; Lisa Stirk, Information Specialist; Catriona McDaid, Senior Research Fellow. Centre for Reviews & Dissemination Acknowledgements With thanks to Professor Philip Hawkins and Professor Mary Reilly who provided clinical advice to the ERG. With thanks to David Epstein for providing advice on the health economics. Date completed 16th July 2012 Declared competing interests of the authors None Page | 1 Table of Contents 1 SUMMARY ..................................................................................................................... 11 1.1 Scope of the Evidence Review Group assessment .................................................. 11 1.2 Scope of the manufacturer submission .................................................................... 11 1.3 Summary of submitted clinical effectiveness evidence ............................................ 11 1.4 Summary of submitted cost effectiveness evidence ................................................. 12 1.5 Summary of additional work undertaken by the ERG ............................................... 14 1.6 Commentary on the robustness of submitted evidence ..........................................
    [Show full text]
  • VYNDAQEL Are Not Substitutable on a Per Mg Basis
    HIGHLIGHTS OF PRESCRIBING INFORMATION • VYNDAMAX and VYNDAQEL are not substitutable on a per mg basis. These highlights do not include all the information needed to use (2.1) VYNDAQEL and VYNDAMAX safely and effectively. See full prescribing information for VYNDAQEL and VYNDAMAX. --------------------- DOSAGE FORMS AND STRENGTHS --------------------­ Capsules: Tafamidis meglumine 20 mg and tafamidis 61 mg. (3) VYNDAQEL® (tafamidis meglumine) capsules, for oral administration Initial U.S. Approval: 2019 ------------------------------ CONTRAINDICATIONS -----------------------------­ None. (4) VYNDAMAXTM (tafamidis) capsules, for oral administration Initial U.S. Approval: 2019 To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. --------------------------- INDICATIONS AND USAGE ---------------------------­ VYNDAQEL and VYNDAMAX are transthyretin stabilizers indicated for the ----------------------- USE IN SPECIFIC POPULATIONS ----------------------­ treatment of the cardiomyopathy of wild type or hereditary • Pregnancy: Based on animal studies, may cause fetal harm. (8.1) transthyretin-mediated amyloidosis in adults to reduce cardiovascular • Lactation: Advise not to breastfeed. (8.2) mortality and cardiovascular-related hospitalization. (1) See 17 for PATIENT COUNSELING INFORMATION and ----------------------- DOSAGE AND ADMINISTRATION ----------------------­ FDA-approved patient labeling. The recommended dosage is either: Revised: 05/2019 • VYNDAQEL 80 mg orally once
    [Show full text]
  • Design and Rationale of the Phase 3 Tafamidis in Transthyretin Cardiomyopathy
    Design and Rationale of the Phase 3 Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) Mathew S. Maurer, MD; Perry Elliott, MD; Giampaolo Merlini, PhD; Sanjiv J. Shah, MD; Márcia Waddington Cruz, MD; Alison Flynn, BSN; Balarama Gundapaneni, MAS; Carolyn Hahn, BA; Steven Riley, PharmD, PhD; Jeffrey Schwartz, PhD; Marla B. Sultan, MD, MBA; Claudio Rapezzi, MD; on behalf of the ATTR-ACT Study Investigators From Columbia University College of Physicians and Surgeons, New York, NY (M.S.M); University College London, London, UK (P.E); IRCCS Policlinico San Matteo and University of Pavia, Pavia, Italy (G.M.); Northwestern University, Chicago, IL (S.J.S); Federal University of Rio de Janeiro, National Amyloidosis Referral Center, CEPARM, Rio de Janeiro, Brazil (M.W.C.); Pfizer Inc, Collegeville, PA (A.F., C.H.); inVentiv Health, Burlington, MA (B.G.); Pfizer Inc, Groton, CT (S.R., J.S.); Pfizer Inc, New York, NY (M.B.S); and the University of Bologna, Bologna, Italy (C.R). Correspondence to Mathew S. Maurer, MD, Clinical Cardiovascular Research Laboratory for the Elderly (CCRLE), Columbia University Medical Center, Allen Hospital of New York Presbyterian Hospital, 5141 Broadway, 3 Field W, Room 035, New York, NY 10034 . E-mail [email protected] Running head (49/50 characters with spaces max): Maurer et al Tafamidis in TTR-CM Clinical Trial Word count ~5688 (max 6000 words; includes title page, abstract, text, references, tables, and figure legends) References 49 (max 50) Transthyretin cardiomyopathy (TTR-CM) is a rare,
    [Show full text]
  • The Clinical Trial Landscape in Amyotrophic Lateral Sclerosis—Past, Present, and Future
    Received: 16 September 2019 | Revised: 8 December 2019 | Accepted: 27 January 2020 DOI: 10.1002/med.21661 REVIEW ARTICLE The clinical trial landscape in amyotrophic lateral sclerosis—Past, present, and future Heike J. Wobst1 | Korrie L. Mack2,3 | Dean G. Brown4 | Nicholas J. Brandon1 | James Shorter2 1Neuroscience, BioPharmaceuticals R&D, AstraZeneca, Boston, Massachusetts Abstract 2 Department of Biochemistry and Biophysics, Amyotrophic lateral sclerosis (ALS) is a fatal neurodegen- Perelman School of Medicine, University of erative disease marked by progressive loss of muscle func- Pennsylvania, Philadelphia, Pennsylvania ‐ 3Merck & Co, Inc, Kenilworth, New Jersey tion. It is the most common adult onset form of motor 4Hit Discovery, Discovery Sciences, neuron disease, affecting about 16 000 people in the United BioPharmaceuticals R&D, AstraZeneca, Boston, States alone. The average survival is about 3 years. Only two Massachusetts interventional drugs, the antiglutamatergic small‐molecule Correspondence riluzole and the more recent antioxidant edaravone, have Heike J. Wobst, Jnana Therapeutics, Northern been approved for the treatment of ALS to date. Therapeutic Avenue, Boston, MA 02210. Email: [email protected] strategies under investigation in clinical trials cover a range of different modalities and targets, and more than 70 dif- James Shorter, Department of Biochemistry and Biophysics, Perelman School of Medicine, ferent drugs have been tested in the clinic to date. Here, we University of Pennsylvania, Philadelphia, PA summarize and classify interventional therapeutic strategies 19104. Email: [email protected] based on their molecular targets and phenotypic effects. We also discuss possible reasons for the failure of clinical trials in Present address Heike J. Wobst, Dean G.
    [Show full text]
  • Mrx CLINICAL ALERT
    MRx JUNE 2019 CLINICAL ALERT YOUR MONTHLY SOURCE FOR DRUG INFORMATION HIGHLIGHTS HOT TOPIC: completed 2-year START trial (n=12, GENE THERAPY APPROVED therapeutic cohort). Both studies EDITORIAL FOR SPINAL MUSCULAR enrolled patients with SMA type 1. ATROPHY Treatment with Zolgensma led to STAFF significant improvement in reaching The United States (US) Food and developmental motor milestones, Drug Administration (FDA) approved such as head control, sitting without EDITOR IN CHIEF onasemnogene abeparvovec-xioi support, and/or standing/walking ® Maryam Tabatabai (Zolgensma ) for the treatment of without assistance compared to the PharmD patients < 2 years of age with spinal natural history of the disease. A durable muscular atrophy (SMA) who have effect of nearly 4 years was reported bi-allelic mutations in the survival in the START long-term follow-up. EXECUTIVE EDITOR motor neuron 1 (SMN1) gene, which Zolgensma carries a Boxed warning Carole Kerzic instructs production of a protein critical for acute serious liver injury. RPh for motor neuron function. SMA is the leading genetic cause of infant Avexis/Novartis set a wholesale DEPUTY EDITORS mortality. The most common form, SMA acquisition cost (WAC) of $2.125 million Jill Bot type 1, occurs in about 1 in 10,000 for the 1-time Zolgensma dose, making PharmD newborns, leading to about 500 new it the world’s most expensive drug. cases per year in the US. Patients with The Institute for Clinical and Economic Stephanie Christofferson SMA type 1 experience progressive Review (ICER) published a value-based PharmD motor function decline beginning price benchmark for Zolgensma of $1.2 shortly after birth.
    [Show full text]